Mental health and cognitive function responses to quetiapine in patients with methamphetamine abuse under methadone maintenance treatment
•This study has evaluated the effects of quetiapine intake in MA abuse under MMT.•Quetiapine in MA abuse under MMT improved sleep and depression.•Quetiapine in MA abuse under MMT improved cognitive function. Patients with methamphetamine (MA) abuse under methadone maintenance treatment (MMT) are sus...
Gespeichert in:
| Veröffentlicht in: | Journal of affective disorders 2019-05, Vol.251, p.235-241 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 241 |
|---|---|
| container_issue | |
| container_start_page | 235 |
| container_title | Journal of affective disorders |
| container_volume | 251 |
| creator | Javdan, Najme Sadat Ghoreishi, Fatemeh Sadat Sehat, Mojtaba Ghaderi, Amir Banafshe, Hamid Reza |
| description | •This study has evaluated the effects of quetiapine intake in MA abuse under MMT.•Quetiapine in MA abuse under MMT improved sleep and depression.•Quetiapine in MA abuse under MMT improved cognitive function.
Patients with methamphetamine (MA) abuse under methadone maintenance treatment (MMT) are susceptible to several complications including cognitive disturbance and mental health disorder. This trial was designed to determine the impacts of quetiapine administration on cognitive function and mental health scale in patients with MA abuse under MMT.
This study was carried out in 60 MA abusers under MMT. Patients were randomly allocated to receive either 100 mg quetiapine (n = 30) or control (n = 30) daily for 8 weeks. Cognitive function and mental health scale were taken at baseline and post-treatment to evaluate relevant variables.
Quetiapine significantly decreased depression (b -3.94; 95% CI, -7.73, -0.16; P = 0.04) and sleep disorder (b -2.18; 95% CI, -2.89, -1.47; P |
| doi_str_mv | 10.1016/j.jad.2019.03.078 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2201710612</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0165032719302903</els_id><sourcerecordid>2201710612</sourcerecordid><originalsourceid>FETCH-LOGICAL-c379t-37ac13761561ac95aaf1d367b8c5132a04f7e6d9b016ada01b58cf3065fc5cf63</originalsourceid><addsrcrecordid>eNp9kUFv1DAUhC1ERZeWH8AF-cglqR1jOxEnVNGC1IoLPVsv9gvrVWIH2ynqT-Bf49UWjpwsPX8z0swQ8pazljOurg7tAVzbMT60TLRM9y_Ijkstmk5y_ZLsKiMbJjp9Tl7nfGCMqUGzV-RcsKHreyV25Pc9hgIz3SPMZU8hOGrjj-CLf0Q6bcEWHwNNmNcYMmZaIv25YfGw-oDUB7pC8dUi01--6hcse1jWPRZYjgCMW0a6BYfp9OdivS7gQ8EAwSItCaEs1eGSnE0wZ3zz_F6Qh5vP36-_NHffbr9ef7prrNBDaYQGy4VWXCoOdpAAE3dC6bG3kosO2IdJo3LDWMODA8ZH2dtJMCUnK-2kxAV5f_JdU6xRcjGLzxbnGQLGLZuu9qk5U7yrKD-hNsWcE05mTX6B9GQ4M8cFzMHUBcxxAcOEqQtUzbtn-21c0P1T_K28Ah9PANaQjx6TybY2aNH5hLYYF_1_7P8AjtCaSQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2201710612</pqid></control><display><type>article</type><title>Mental health and cognitive function responses to quetiapine in patients with methamphetamine abuse under methadone maintenance treatment</title><source>Elsevier ScienceDirect Journals</source><creator>Javdan, Najme Sadat ; Ghoreishi, Fatemeh Sadat ; Sehat, Mojtaba ; Ghaderi, Amir ; Banafshe, Hamid Reza</creator><creatorcontrib>Javdan, Najme Sadat ; Ghoreishi, Fatemeh Sadat ; Sehat, Mojtaba ; Ghaderi, Amir ; Banafshe, Hamid Reza</creatorcontrib><description>•This study has evaluated the effects of quetiapine intake in MA abuse under MMT.•Quetiapine in MA abuse under MMT improved sleep and depression.•Quetiapine in MA abuse under MMT improved cognitive function.
Patients with methamphetamine (MA) abuse under methadone maintenance treatment (MMT) are susceptible to several complications including cognitive disturbance and mental health disorder. This trial was designed to determine the impacts of quetiapine administration on cognitive function and mental health scale in patients with MA abuse under MMT.
This study was carried out in 60 MA abusers under MMT. Patients were randomly allocated to receive either 100 mg quetiapine (n = 30) or control (n = 30) daily for 8 weeks. Cognitive function and mental health scale were taken at baseline and post-treatment to evaluate relevant variables.
Quetiapine significantly decreased depression (b -3.94; 95% CI, -7.73, -0.16; P = 0.04) and sleep disorder (b -2.18; 95% CI, -2.89, -1.47; P < 0.001). Also, quetiapine administration resulted in a significant reduction in Iowa Gambling Task (b -2.70; 95% CI, -4.69, -0.71; P = 0.009), and significant increases in Verbal Fluency Test (b 3.04; 95% CI, 1.24, 4.85; P = 0.001), Reverse Digit Span (b 2.80; 95% CI, 2.13, 3.47; P = 0.001) compared with the placebo.
Overall, taking 100 mg quetiapine daily for 8 weeks by patients MA abuse in MMT had favorable effects on some of cognitive functions and mental health parameters.</description><identifier>ISSN: 0165-0327</identifier><identifier>EISSN: 1573-2517</identifier><identifier>DOI: 10.1016/j.jad.2019.03.078</identifier><identifier>PMID: 30928863</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Cognitive functions ; Mental health ; Methadone maintenance treatment ; Quetiapine</subject><ispartof>Journal of affective disorders, 2019-05, Vol.251, p.235-241</ispartof><rights>2019 Elsevier B.V.</rights><rights>Copyright © 2019 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c379t-37ac13761561ac95aaf1d367b8c5132a04f7e6d9b016ada01b58cf3065fc5cf63</citedby><cites>FETCH-LOGICAL-c379t-37ac13761561ac95aaf1d367b8c5132a04f7e6d9b016ada01b58cf3065fc5cf63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0165032719302903$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30928863$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Javdan, Najme Sadat</creatorcontrib><creatorcontrib>Ghoreishi, Fatemeh Sadat</creatorcontrib><creatorcontrib>Sehat, Mojtaba</creatorcontrib><creatorcontrib>Ghaderi, Amir</creatorcontrib><creatorcontrib>Banafshe, Hamid Reza</creatorcontrib><title>Mental health and cognitive function responses to quetiapine in patients with methamphetamine abuse under methadone maintenance treatment</title><title>Journal of affective disorders</title><addtitle>J Affect Disord</addtitle><description>•This study has evaluated the effects of quetiapine intake in MA abuse under MMT.•Quetiapine in MA abuse under MMT improved sleep and depression.•Quetiapine in MA abuse under MMT improved cognitive function.
Patients with methamphetamine (MA) abuse under methadone maintenance treatment (MMT) are susceptible to several complications including cognitive disturbance and mental health disorder. This trial was designed to determine the impacts of quetiapine administration on cognitive function and mental health scale in patients with MA abuse under MMT.
This study was carried out in 60 MA abusers under MMT. Patients were randomly allocated to receive either 100 mg quetiapine (n = 30) or control (n = 30) daily for 8 weeks. Cognitive function and mental health scale were taken at baseline and post-treatment to evaluate relevant variables.
Quetiapine significantly decreased depression (b -3.94; 95% CI, -7.73, -0.16; P = 0.04) and sleep disorder (b -2.18; 95% CI, -2.89, -1.47; P < 0.001). Also, quetiapine administration resulted in a significant reduction in Iowa Gambling Task (b -2.70; 95% CI, -4.69, -0.71; P = 0.009), and significant increases in Verbal Fluency Test (b 3.04; 95% CI, 1.24, 4.85; P = 0.001), Reverse Digit Span (b 2.80; 95% CI, 2.13, 3.47; P = 0.001) compared with the placebo.
Overall, taking 100 mg quetiapine daily for 8 weeks by patients MA abuse in MMT had favorable effects on some of cognitive functions and mental health parameters.</description><subject>Cognitive functions</subject><subject>Mental health</subject><subject>Methadone maintenance treatment</subject><subject>Quetiapine</subject><issn>0165-0327</issn><issn>1573-2517</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kUFv1DAUhC1ERZeWH8AF-cglqR1jOxEnVNGC1IoLPVsv9gvrVWIH2ynqT-Bf49UWjpwsPX8z0swQ8pazljOurg7tAVzbMT60TLRM9y_Ijkstmk5y_ZLsKiMbJjp9Tl7nfGCMqUGzV-RcsKHreyV25Pc9hgIz3SPMZU8hOGrjj-CLf0Q6bcEWHwNNmNcYMmZaIv25YfGw-oDUB7pC8dUi01--6hcse1jWPRZYjgCMW0a6BYfp9OdivS7gQ8EAwSItCaEs1eGSnE0wZ3zz_F6Qh5vP36-_NHffbr9ef7prrNBDaYQGy4VWXCoOdpAAE3dC6bG3kosO2IdJo3LDWMODA8ZH2dtJMCUnK-2kxAV5f_JdU6xRcjGLzxbnGQLGLZuu9qk5U7yrKD-hNsWcE05mTX6B9GQ4M8cFzMHUBcxxAcOEqQtUzbtn-21c0P1T_K28Ah9PANaQjx6TybY2aNH5hLYYF_1_7P8AjtCaSQ</recordid><startdate>20190515</startdate><enddate>20190515</enddate><creator>Javdan, Najme Sadat</creator><creator>Ghoreishi, Fatemeh Sadat</creator><creator>Sehat, Mojtaba</creator><creator>Ghaderi, Amir</creator><creator>Banafshe, Hamid Reza</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20190515</creationdate><title>Mental health and cognitive function responses to quetiapine in patients with methamphetamine abuse under methadone maintenance treatment</title><author>Javdan, Najme Sadat ; Ghoreishi, Fatemeh Sadat ; Sehat, Mojtaba ; Ghaderi, Amir ; Banafshe, Hamid Reza</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c379t-37ac13761561ac95aaf1d367b8c5132a04f7e6d9b016ada01b58cf3065fc5cf63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Cognitive functions</topic><topic>Mental health</topic><topic>Methadone maintenance treatment</topic><topic>Quetiapine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Javdan, Najme Sadat</creatorcontrib><creatorcontrib>Ghoreishi, Fatemeh Sadat</creatorcontrib><creatorcontrib>Sehat, Mojtaba</creatorcontrib><creatorcontrib>Ghaderi, Amir</creatorcontrib><creatorcontrib>Banafshe, Hamid Reza</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of affective disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Javdan, Najme Sadat</au><au>Ghoreishi, Fatemeh Sadat</au><au>Sehat, Mojtaba</au><au>Ghaderi, Amir</au><au>Banafshe, Hamid Reza</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mental health and cognitive function responses to quetiapine in patients with methamphetamine abuse under methadone maintenance treatment</atitle><jtitle>Journal of affective disorders</jtitle><addtitle>J Affect Disord</addtitle><date>2019-05-15</date><risdate>2019</risdate><volume>251</volume><spage>235</spage><epage>241</epage><pages>235-241</pages><issn>0165-0327</issn><eissn>1573-2517</eissn><abstract>•This study has evaluated the effects of quetiapine intake in MA abuse under MMT.•Quetiapine in MA abuse under MMT improved sleep and depression.•Quetiapine in MA abuse under MMT improved cognitive function.
Patients with methamphetamine (MA) abuse under methadone maintenance treatment (MMT) are susceptible to several complications including cognitive disturbance and mental health disorder. This trial was designed to determine the impacts of quetiapine administration on cognitive function and mental health scale in patients with MA abuse under MMT.
This study was carried out in 60 MA abusers under MMT. Patients were randomly allocated to receive either 100 mg quetiapine (n = 30) or control (n = 30) daily for 8 weeks. Cognitive function and mental health scale were taken at baseline and post-treatment to evaluate relevant variables.
Quetiapine significantly decreased depression (b -3.94; 95% CI, -7.73, -0.16; P = 0.04) and sleep disorder (b -2.18; 95% CI, -2.89, -1.47; P < 0.001). Also, quetiapine administration resulted in a significant reduction in Iowa Gambling Task (b -2.70; 95% CI, -4.69, -0.71; P = 0.009), and significant increases in Verbal Fluency Test (b 3.04; 95% CI, 1.24, 4.85; P = 0.001), Reverse Digit Span (b 2.80; 95% CI, 2.13, 3.47; P = 0.001) compared with the placebo.
Overall, taking 100 mg quetiapine daily for 8 weeks by patients MA abuse in MMT had favorable effects on some of cognitive functions and mental health parameters.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>30928863</pmid><doi>10.1016/j.jad.2019.03.078</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0165-0327 |
| ispartof | Journal of affective disorders, 2019-05, Vol.251, p.235-241 |
| issn | 0165-0327 1573-2517 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2201710612 |
| source | Elsevier ScienceDirect Journals |
| subjects | Cognitive functions Mental health Methadone maintenance treatment Quetiapine |
| title | Mental health and cognitive function responses to quetiapine in patients with methamphetamine abuse under methadone maintenance treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T02%3A23%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mental%20health%20and%20cognitive%20function%20responses%20to%20quetiapine%20in%20patients%20with%20methamphetamine%20abuse%20under%20methadone%20maintenance%20treatment&rft.jtitle=Journal%20of%20affective%20disorders&rft.au=Javdan,%20Najme%20Sadat&rft.date=2019-05-15&rft.volume=251&rft.spage=235&rft.epage=241&rft.pages=235-241&rft.issn=0165-0327&rft.eissn=1573-2517&rft_id=info:doi/10.1016/j.jad.2019.03.078&rft_dat=%3Cproquest_cross%3E2201710612%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2201710612&rft_id=info:pmid/30928863&rft_els_id=S0165032719302903&rfr_iscdi=true |